Article Text

Download PDFPDF

P19 Autoantibody profile analysis in SLE patients
  1. Marta De-la-Rubia-Navarro1,
  2. Elena Grau-García1,
  3. Samuel Leal-Rodríguez1,
  4. Cristóbal Pávez-Perales1,
  5. Cristóbal Alcañiz-Escandell1,
  6. Inés Cánovas-Olmos1,
  7. Inmaculada Chalmeta-Verdejo1,
  8. Jorge Juan Fragio-Gil1,
  9. Roxana González-Mazarío1,
  10. Luis González-Puig1,
  11. José Ivorra-Cortés1,
  12. Isabel Martínez-Cordellat1,
  13. Carmen Nájera-Herranz1,
  14. Rosa Negueroles-Albuixech1,
  15. José Eloy Oller-Rodríguez1,
  16. Francisco Miguel Ortiz-Sanjuán1,
  17. Elvira Vicens-Bernabeu1,
  18. Daniel Hervás-Marín2,
  19. Meritxel Fernández Matilla3,
  20. Nagore Fernández-Llanio Comella3,
  21. Juan Antonio Castellano Cuesta3 and
  22. José Andrés Román-Ivorra1
  1. 1Rheumatology Dept., HUP-La-Fe, Valencia
  2. 2Biostatistics Unit, IIS-La-Fe, Valencia
  3. 3Rheumatology Section, Hospital-Arnau-de-Vilanova, Valencia, Spain


Background/Purpose In Systemic Lupus Erythematosus (SLE) the presence of some autoantibodies is related to specific clinical manifestations. We aimed to define SLE patient groups according to an autoantibody profile and to analyze the correlation of these profiles to clinical manifestations.

Methods A cross-sectional observational study of SLE (SLICC 2012 criteria) was conducted. A clinical and analytical evaluation was performed. Clinical manifestations were described according to RELESSER study.

We selected 8 autoantibodies to classify SLE patients: anti-dsDNA, anti-Sm, anti-RNP, anticardiolipin IgG/IgM (aCL IgG/M), anti-ß2microglobulin IgG/IgM (aß2M IgG/M), lupus anticoagulant (LA), anti-Ro and anti-La. Immunological profiles were created according to previous study of Artim-Esen B et al. 2014.

Results 142 SLE patients with a mean age at diagnosis of 33.29 (13.53) and a mean time of disease evolution of 15.82 (10.56) years were evaluated. Mean SLEDAI score was 5.91 (5.6) and mean SLICC value 1.1 (1.46). Autoantibody frequencies are: ANAs 87.3%, anti-dsDNA 36.62%, anti-Sm 9.2%, anti-RNP 3.5%, aCL IgG/M 20.15%, aß2M IgG/M 21.88%, LA 26.27%, anti-Ro 45.07% and anti-La 16.2%.

Profile n°2 included SLE patients with anti-Sm/RNP positivity. Profile n°3 included patients with anti-Ro/La positivity. Profile n°4 included patients with aCL IgG/M or aB2M IgG/M or LA positivity. Profile n°5 included patients who exclusively showed anti-DNA positivity. Profile n°1 included all patients excluded from the other profiles.

Profile n°1 patients were diagnosed earlier and had a longer disease evolution, whereas Profile n°5 patients were diagnosed later and with shorter disease evolution.

We observed a significant association among hematological affection and high levels of anti-Ro (P<0.0001), anti-La (P=0.022) and anti-Sm (P=0.018) was observed.

Conclusions An association between the presence of anti-Ro/La and hematological affection, as well as high incidence of Sjögren syndrome in these subgroup of patients was described.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.